<DOC>
	<DOCNO>NCT01141712</DOCNO>
	<brief_summary>This study Phase II , multicenter trial assess overall survival autologous hematopoietic stem cell transplantation use BEAM transplant regimen ( carmustine , etoposide , cytarabine , melphalan ) lymphoma patient HIV .</brief_summary>
	<brief_title>Autologous Transplant HIV Patients ( BMT CTN 0803 )</brief_title>
	<detailed_description>BACKGROUND : Non-Hodgkin lymphoma ( NHL ) AIDS-defining diagnosis patient infected Human Immunodeficiency Virus ( HIV ) . While incidence NHL decrease amongst HIV-infected patient since advent highly-active anti-retroviral therapy ( HAART ) , lymphoma remain significant cause death patient population . The prognosis patient AIDS-related lymphoma dramatically different era HAART therapy . In comparison treatment outcomes patient treated advent HAART , statistically significant improvement overall survival patient treat HAART . Unfortunately , despite considerable advance treatment AIDS-related NHL , induction-failure disease relapse remain key challenge . The prognosis patient refractory relapse NHL poor overall survival rate less 20 percent patient treat non-transplant salvage therapy . Based upon randomized trial numerous phase II trial , high-dose therapy autologous hematopoietic cell transplantation ( HCT ) establish standard care patient chemotherapy-sensitive relapsed non-Hodgkin lymphoma . DESIGN NARRATIVE : All patient must chemosensitive disease demonstrate response induction salvage chemotherapy . Patients must also less equal 10percent bone marrow involvement recent salvage therapy . Patients prior autologous allogeneic HCT . Patients must initiate conditioning therapy within 3 month mobilization bone marrow harvest . Mobilization therapy may employ per institutional guideline . Patients must adequate autograft eligible protocol . Patients may HIV refractory pharmacologic therapy . Patients must opportunistic infection respond therapy . Patients receive Carmustine ( BCNU ) 300 mg/m^2 Day -6 , Etoposide 100 mg/m^2 twice day ( BID ) Days -5 -2 , Cytarabine 100 mg/m2 BID Days -5 -2 , Melphalan 140 mg/m2 Day -1 follow autologous HCT . Patients follow 2 year post-transplant . Survival data , time progression data , progression-free survival data , time progression Complete Remission ( CR ) data , lymphoma disease-free survival data , time hematopoietic recovery data , hematologic function data , toxicity data , incidence infection , treatment-related mortality data , immunologic reconstitution data , data assess impact therapy HIV reservoir microbial gut translocation record report periodically BMT CTN Data Coordinating Center ( DCC ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Diagnosis persistent recurrent World Health Organization ( WHO ) classification diffuse large Bcell lymphoma , composite lymphoma &gt; 50 % diffuse large Bcell lymphoma , mediastinal Bcell lymphoma , immunoblastic , plasmablastic , Burkitt 's Burkittlike classical Hodgkin 's lymphoma . Patients transform follicular lymphoma eligible study , pending fulfillment criterion . 15 year old old Three few prior regimen chemotherapy entire course disease treatment ( include one induction chemotherapy 2 salvage chemotherapy ) . Monoclonal antibody therapy involve field radiation therapy count prior therapy . All patient must chemosensitive disease demonstrate least partial response induction salvage therapy . Less equal 10 % bone marrow involvement . Patients adequate organ function measure : ) Cardiac : American Heart Association Class I : Patients cardiac disease without result limitation physical activity . Ordinary physical activity cause undue fatigue , palpitation , dyspnea , anginal pain . Additionally , patient must leave ventricular ejection fraction rest great equal 40 % demonstrate Multi Gated Acquisition Scan ( MUGA ) echocardiogram ; b ) Hepatic : ( ) Bilirubin le 2.0 mg/dL ( except isolate hyperbilirubinemia attribute Gilbert syndrome antiretroviral therapy ) alanine transaminase ( ALT ) aspartate transaminase ( AST ) great 3x upper limit normal ; ( ii ) Concomitant Hepatitis : Patients chronic hepatitis B C may enrol trial provide criterion meet . In addition , active viral replication undetectable ( viral load le 500 copies/ml ) hepatitis B DNA level PCR clinical pathologic evidence irreversible chronic liver disease ; c ) Renal : Creatinine clearance ( calculated creatinine clearance permit ) great 40 mL/min ; ) Pulmonary : Carbon Monoxide Diffusing Capacity ( DLCO ) , forced expiratory volume 1 second ( FEV1 ) , force vital capacity ( FVC ) great equal 45 % predict ( correct hemoglobin ) . Autologous peripheral stem cell graft minimum great less 1.5 x 10^6 CD 34+ cells/kg ( target great less 2.0 x 10^6 CD 34+ cells/kg ) peripheral blood stem cell ( PBSC ) mobilization fails , cell obtain bone marrow harvest per institutional practice ( case bone marrow use transplantation , require CD34+ dose apply institutional requirement total nucleated cell dose apply ) . Initiate conditioning therapy within 3 month mobilization bone marrow harvest . Signed informed consent . Patients antiretroviral therapy ( ARVs ) either : ) Undetectable HIV viral load ( VL le 50 copy ) ; b ) If VL detectable le 2000 copies/mL must review previous antiretroviral regimen previous genotypic phenotypic test indicate ability fully suppress virus addition sensitive drug . This review carry Infectious Disease ( ID ) specialist care patient ; c ) If VL detectable great 2000 copies/mL , current HIV genotype and/or phenotype must obtain . If HAART regimen patient 's virus sensitive determine base genotype previous antiretroviral experience , patient consider eligible regard . This review carry ID specialist care patient . Karnofsky performance score le 70 % . Uncontrolled bacterial , viral fungal infection ( currently take medication progression clinical improvement ) . Prior malignancy 5 year prior enrollment except resect basal cell carcinoma , treat cervical carcinoma situ Kaposi 's sarcoma : ) Symptomatic Kaposi 's sarcoma currently require therapy exclude ( patient receive topical therapy minimal disease include definition ) ; b ) Prior treatment topical agent , local radiation , 6 cycle cytotoxic chemotherapy least six month prior permit ; c ) Other cancer treat curative intent le 5 year previously allow unless approve Medical Monitor Protocol Chair ; ) Cancer treat curative intent 5 year previously allow . Pregnant ( positive Î²HCG ) breastfeeding . Fertile men woman unwilling use contraceptive technique time initiation mobilization sixmonths posttransplant . Prior autologous allogeneic HCT . Patients evidence Myelodysplastic Syndrome ( MDS ) /Acute Myeloid Leukemia ( AML ) abnormal cytogenetic analysis indicative MDS pretransplant bone marrow examination . Pathology report documentation need submit .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>B-cell Lymphoma</keyword>
	<keyword>Burkitt 's Lymphoma</keyword>
	<keyword>Follicular Lymphoma</keyword>
	<keyword>Hodgkin 's Lymphoma</keyword>
</DOC>